JMBI-001

JMBI-001 is an oral tablet (small molecule not stated) from Anticancer Bioscience, with Peking University Cancer Hospital & Institute as partner. Tested in adults with MYC-positive advanced cancers; the company describes its work as MYC synthetic lethality, but no source states JMBI-001's molecular target. Its furthest stage is phase 1, for MYC-positive advanced solid tumours and relapsed or refractory non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 recruiting, start October 2026 (NCT07864701). Whether it works in people has not been established unless a trial below reports it.